Status
Conditions
Treatments
About
The purpose of this study is to:
Full description
Tripterygium (TW) is a Chinese traditional patent drugs in treating chronic glomerulonephritis. It has been used to treat lupus nephritis for many years with less side effects. We compare the efficacy and safety of TW vs Aza in the maintenance therapy of lupus nephritis.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Patients who signed written informed consent form;
SLE patient, aged between 18-60 years, female or male;
Patients diagnosed lupus nephritis according to ISN/RPS 2003 classification criteria, class Ⅲ, Ⅳ,Ⅳ+Ⅴ, Ⅲ+Ⅴ or Ⅴ LN by renal biopsy;
All patients received induction therapy for 6-12 months, including MMF, CTX, FK506 or multi-target therapy;
When recruited in the study, patients received partial remission or complete remission for 3 months;
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
94 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal